SANA BIOTECHNOLOGY INC. - COMMON STOCK

Sana Biotechnology Reports Third Quarter 2023 Financial Results and Business Updates

08 ноя 2023 16:05:01 Источник Nasdaq GlobeNewswire

Sana Biotechnology Announces Five Presentations at the 65th American Society of Hematology Annual Meeting

02 ноя 2023 09:05:00 Источник Nasdaq GlobeNewswire

Sana Biotechnology Announces Increased Focus on Hypoimmune-Related Pipeline with the Potential to Deliver Clinical Proof of Concept Data from Four Programs in 2023 and 2024 with a 2024 Operating Burn under $200M

10 окт 2023 16:15:00 Источник Nasdaq GlobeNewswire

Sana Biotechnology to Present at September 2023 Investor Conferences

30 авг 2023 16:05:00 Источник Nasdaq GlobeNewswire

Sana Biotechnology Reports Second Quarter 2023 Financial Results and Business Updates

03 авг 2023 16:05:01 Источник Nasdaq GlobeNewswire

Sana Biotechnology Highlights Preclinical Data from Hypoimmune and Fusogen Platforms at the International Society for Stem Cell Research (ISSCR) 2023 Annual Meeting

16 июн 2023 09:00:00 Источник Nasdaq GlobeNewswire

Sana Biotechnology to Present at June 2023 Investor Conferences

31 май 2023 16:05:00 Источник Nasdaq GlobeNewswire

Sana Biotechnology Announces Preclinical Data Published in Nature Biotechnology Demonstrating its Hypoimmune-Engineered Cells Escape Immune Detection and Survive While Remaining Fully Functional

08 май 2023 16:35:00 Источник Nasdaq GlobeNewswire

Sana Biotechnology Reports First Quarter 2023 Financial Results and Business Updates

08 май 2023 16:05:01 Источник Nasdaq GlobeNewswire

Sana Biotechnology to Present at May 2023 Investor Conferences

03 май 2023 16:05:01 Источник Nasdaq GlobeNewswire

Sana Biotechnology Announces the Acceptance of Six Abstracts for Presentation at the American Society of Gene and Cell Therapy (ASGCT) 26th Annual Meeting

02 май 2023 16:30:00 Источник Nasdaq GlobeNewswire

Sana Biotechnology to Host Research & Development Day

24 апр 2023 16:06:02 Источник Nasdaq GlobeNewswire

Sana Biotechnology Highlights Preclinical Hypoimmune Data for its Allogeneic CAR T Platform and Advancements with its In Vivo Fusogen Platform with Four Presentations at the 2023 AACR Annual Meeting

19 апр 2023 16:05:00 Источник Nasdaq GlobeNewswire

Sana Biotechnology Announces Preclinical Data Published in Nature Communications Demonstrating the Ability of its Hypoimmune Allogeneic CD19-directed CAR T Cells to Evade Immune Rejection and Produce Durable Anti-Tumor Responses

13 апр 2023 09:00:01 Источник Nasdaq GlobeNewswire

Sana Biotechnology Announces Preclinical Data Published in Science Translational Medicine Showing its Hypoimmune Pancreatic Islet Cells Evaded Allogeneic and Autoimmune Rejection and Controlled Type 1 Diabetes in Preclinical Model

12 апр 2023 16:05:00 Источник Nasdaq GlobeNewswire

Sana Biotechnology Announces the Appointment of Two Pioneers in Drug Discovery and Development to Lead its R&D Organization

10 апр 2023 16:05:00 Источник Nasdaq GlobeNewswire

Sana Biotechnology Reports Fourth Quarter and Full Year 2022 Financial Results and Business Updates

16 мар 2023 16:05:00 Источник Nasdaq GlobeNewswire

Sana Biotechnology Announces the Acceptance of Four Abstracts for Presentation at the 2023 American Association for Cancer Research Annual Meeting

14 мар 2023 16:53:13 Источник Nasdaq GlobeNewswire

Sana Biotechnology to Present at the Cowen 43rd Annual Health Care Conference

01 мар 2023 16:05:00 Источник Nasdaq GlobeNewswire

Sana Biotechnology to Present at the Guggenheim Healthcare Talks 5th Annual Oncology Conference

02 фев 2023 16:05:00 Источник Nasdaq GlobeNewswire